Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...

Key Takeaways Novo Nordisk's U.S.-listed shares fell Monday after it released the latest results for its developmental weight ...

Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest ...

STORY: Shares of Novo Nordisk tumbled 10% Monday morning after the drugmaker revealed weaker-than-expected data about its ...

Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that ...

Novo’s share price fell 8 per cent on Monday, having previously dived in December after a late-stage trial of CagriSema in overweight or obese people without diabetes found they lost an average of ...

Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial. Novo's results from its Redefine 2 late-stage trial of ...

Novo Nordisk shares fell after the pharmaceutical giant released fresh trial results for its CagriSema developmental weight-loss drug. The Danish company said CagriSema helped obese or overweight ...